Noxopharm Ltd. · ASX:NOX
Noxopharm — Shareholder Meeting (November 2026)
26 slides from Noxopharm's shareholder meeting presentation, Nov 17, 2026
Slide 1: Noxopharm 2026 AGM Corporate Presentation
Noxopharm 2026 AGM Corporate Presentation For personal use only Sydney, 17 November 2026: Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to release its 2026 AGM Corporate Presentation. Highlights: • Upcoming lupus patient study • Strong and diverse pipeline • Significant global ma
Slide 2: Forward Looking Statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” For pe
Slide 3: Developing precision therapies for chronic inflammation, autoimmune diseases and cancer
rsonal use only Developing precision therapies for chronic inflammation, autoimmune diseases and cancer Noxopharm (ASX:NOX) AGM Presentation 17 November 2026 1
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Noxopharm Limited (Noxopharm, NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in N
Slide 5: Harnessing the immune system to fight disease
Harnessing the immune system to fight disease Australian clinical-stage biotechnology company developing novel targeted immuno-therapies for chronic inflammation, autoimmune diseases and cancer rsonal use only Proprietary Sofra platform • Built upon a newly discovered role of natural RNA (Ribonuclei
Slide 6: Our platform
Our platform Developing proprietary synthetic RNA-based medicines (oligonucleotides) Market opportunity for precise, targeted rsonal use only >50% of all deaths are linked to inflammation 1 therapies in place of broad immune suppression OUR SOLUTION The Sofra Tech Platform Turning natural RNA immune
Slide 7: How does Sofra technology work?
How does Sofra technology work? Translating naturally occurring immune-control into targeted medicines 1 2 3 4 rsonal use only Sofra decodes it from Sofra encoded RNA Application potential Nature’s off-switch discovery natural RNA medicines across therapeutic areas Natural RNA fragments help keep in
Slide 8: A strong and diverse pipeline
A strong and diverse pipeline A single technology platform supporting multiple immuno-therapy approaches Program Focus MoA Partner Discovery PoC IND-enabling Clinical rsonal use only SOF-SKN Topical therapy; initial focus on cutaneous lupus erythematosus TLR7/8 Internal Phase I complete; Phase II pr
Slide 9: Lead asset and clinical progress
rsonal use only Lead asset and clinical progress AUTOIMMUNE DISEASES / INFLAMMATION 7
Slide 10: SOF-SKN innovation at a glance
SOF-SKN innovation at a glance Lead clinical asset for cutaneous lupus erythematosus (CLE) An autoimmune Unmet need for well SOF-SKN is a rsonal use only Cutaneous lupus What is disease that can affect erythematosus (CLE) tolerated targeted topical clinical Lupus? different organs. manifests in the
Slide 11: Targeting global dermatology markets
Targeting global dermatology markets Initial focus on CLE valued at US$5.4 billion (2024) with no current targeted therapies Potential expansion into adjacent inflammatory skin diseases Selected inflammatory skin disease TAM rsonal use only ~US$43B (2025E) → ~US$56B (2034F) INITIAL CLINICAL ENTRY PO
Slide 12: SOF-SKN: mechanism of action
SOF-SKN: mechanism of action Targeting overactive TLR7/8 signalling at the source of skin inflammation SOF-SKN promotes healing Overactive immune Targeted approach to Its active ingredient, rsonal use only receptors Toll-like SOF-SKN is applied reduce inflammatory TLR7/8 is a SOF-16, is designed rec
Slide 13: The SOF-SKN competitive advantage
The SOF-SKN competitive advantage How SOF-SKN compares on clinical stage, mechanism, safety and durability Approved CLE Emerging oral SOF-SKN rsonal use only Therapies TLR7/8 inhibitors Enpatoran (Merck) / Topical TLR7/8 Kenalog / Plaquenil Inhibitor Afimetoran (BMS) Clinical stage In market Phase I
Slide 14: Progressive clinical trial strategy
Progressive clinical trial strategy Accelerating SOF-SKN’s clinical development in patients with CLE rsonal use only Q1 2027 Q4 2027 Extension First patient treatment Q2 2027 Full clinical data readout – Potential initial efficacy Study (15 patients, 14 days’ daily signals in patients potential effi
Slide 15: Platform opportunities
rsonal use only Platform opportunities mRNA VACCINE ADJUVANCY IMMUNO- ONCOLOGY 13
Slide 16: SOF-16 – External collaborations across multiple indications
SOF-16 – External collaborations across multiple indications Development through MTAs 3 examples shown + additional opportunities rsonal use only SOF-16 in progress Lung Inflammation Rheumatoid Arthritis Antibody-drug conjugate InhaTarget, Belgium Tezcat, US BioRay, China In vivo US$16.2B Patient- U
Slide 17: Tuning the immune system for mRNA vaccines and immuno-oncology
Tuning the immune system for mRNA vaccines and immuno-oncology SOF-VAC and SOF-CAN use the same underlying oligonucleotide technology rsonal use only Sofra Platform Encoding immune control into synthetic RNA oligonucleotides allows precision tuning of the immune system in two directions Targeted imm
Slide 18: SOF-VAC - Enhancing mRNA medicines and vaccines
SOF-VAC - Enhancing mRNA medicines and vaccines Designed to limit side effects of mRNA vaccines SOF-VAC - mechanism of action Key advantages rsonal use only Reduces off-target reactogenic side effects of mRNA vaccines Enables potential for higher mRNA doses, increasing efficacy while maintaining saf
Slide 19: SOF-CAN – Precision immune activation to fight cancer
SOF-CAN – Precision immune activation to fight cancer Precision immune activation for next-generation cancer immunotherapy Current progress How SOF-CAN works and key advantages rsonal use only Ex vivo proof-of-concept announced, R&D at late-stage lead optimisation Toll-like receptor 8 (TLR8) in immu
Slide 20: Multiple opportunities in mRNA vaccines and immuno-oncology
Multiple opportunities in mRNA vaccines and immuno-oncology SOF-VAC and SOF-CAN use the same underlying oligonucleotide technology Technologies supporting higher, safer doses of mRNA Technologies selectively activating the immune system rsonal use only mRNA VACCINE ADJUVANCY IMMUNO-ONCOLOGY SOF-VAC
Slide 21: IP, financials & catalysts
rsonal use only IP, financials & catalysts 19
Slide 22: Comprehensive IP strategy
Comprehensive IP strategy A growing patent portfolio supporting the Sofra platform and lead programs Long-term collaboration with Hudson Institute of Key HIMR collaboration discoveries were exclusively licensed to Noxopharm in Medical Research (HIMR) enabling ongoing research 2021. Four core patent
Slide 23: Financials
Financials Key corporate and market information ASX code: NOX rsonal use only GICS classification: Pharmaceuticals, Biotechnology & Life Sciences Latest share price: $0.036 (as at 11/11/26) Market capitalisation $12.02M Shares on issue1: 334,091,502 52-week high: $0.110 52-week low: $0.032 Average d
Slide 24: Near-term milestones and catalysts
Near-term milestones and catalysts Multiple potential value drivers over the next 12 months Next 12 months rsonal use only Systemic SOF-VAC SOF-CAN SOF-SKN autoimmune First patients First potential Confirmation of SOF-SKN PoC in vivo data from New collaborations Oncology in vivo recruited into effic
Slide 25: Q&A
rsonal use only Q&A 23
Slide 26: For more information, please contact
rsonal use only Noxopharm (ASX:NOX) For more information, please contact: Dr Olivier Laczka Chief Executive Officer E: Olivier.laczka@noxopharm.com P: +61 2 9144 2223 Website: www.noxopharm.com